Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277 · View on ClinicalTrials.gov ↗
Study Summary
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the opportunity to receive an additional 156 weeks of treatment with tirzepatide as well as continuing the lifestyle intervention.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Texas
- Driscoll Children's Hospital — Corpus Christi
- Epic Medical Research - DeSoto — DeSoto
- Valley Institute of Research - Fort Worth — Fort Worth
- Consano Clinical Research, LLC — Shavano Park
- Texas Valley Clinical Research — Weslaco
Other
- Investigaciones Medicas Imoba Srl — Buenos Aires
- Centro de Investigaciones Metabólicas (CINME) — Buenos Aires
- Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada — Buenos Aires
- Fundación Respirar — Buenos Aires
- DIM Clínica Privada — Ramos Mejía
California
- Children's Hospital Los Angeles — Los Angeles
- Sutter Valley Medical Foundation (SVMF) Pediatric Endocrinology — Sacramento
New York
- UBMD Pediatrics — Buffalo
- SUNY Upstate Medical University — Syracuse
Delaware
- Nemours Children's Health - Delaware — Wilmington
Georgia
- CenExel iResearch, LLC — Decatur
Idaho
- Medical Research Partners — Ammon
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2030-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06439277
The ClinicalTrials.gov registry entry for NCT06439277 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 704 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06439277 reports 20 study locations spanning 10 distinct geographic areas — top geographies include Texas, Other, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06439277 about?
NCT06439277 is a clinical study titled "A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)". The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may includ...
What is the current status of trial NCT06439277?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2024-06-03. Estimated completion is 2030-12.
What conditions does trial NCT06439277 study?
This clinical trial studies the following conditions: Obesity, Weight Gain. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06439277?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06439277?
This trial is sponsored by Eli Lilly and Company, which has 704 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06439277 being conducted?
This trial has 20 study locations across California, Delaware, Georgia, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.